Last week, the pharmaceutical industry in India was hit by two pieces of bad
news.

In a report released by the US Chamber of Commerce, the country was ranked the
worst in the world for enforcing trademarks, patents and other intellectual
property, scoring a dismal 6.95 on a 30-point index. That was nearly half
the 11.95 points scored by China and 27.59 for Britain.

On the same day, AstraZeneca — the world’s seventh-biggest drugmaker —
announced that it was shutting its global research and development plant in
Bangalore, with the loss of nearly 200 skilled